The Medical Letter on Drugs and Therapeutics
Triumeq: A 3-Drug Combination for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine, for once-daily treatment of HIV-1 infection. Dolutegravir (Tivicay) was approved as a single agent in 2013.1

TREATMENT OF HIV – First-line therapy for HIV usually consists of two NRTIs in combination with a third antiretroviral drug from one of three drug classes: a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) boosted with ritonavir, or an INSTI.2,3 Dolutegravir plus abacavir and lamivudine is a recommended INSTI-based regimen for treatment-naive patients (Table 1).

CLINICAL STUDIES – FDA approval of Triumeq was ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Triumeq: A 3-Drug Combination for HIV
Article code: 1459e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian